SANDOZ CEFTRIAXONE POWDER FOR SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
28-01-2010
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
CEFTRIAXONE (CEFTRIAXONE SODIUM)
Tillgänglig från:
SANDOZ CANADA INCORPORATED
ATC-kod:
J01DD04
INN (International namn):
CEFTRIAXONE
Dos:
2G
Läkemedelsform:
POWDER FOR SOLUTION
Sammansättning:
CEFTRIAXONE (CEFTRIAXONE SODIUM) 2G
Administreringssätt:
INTRAMUSCULAR
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
THIRD GENERATION CEPHALOSPORINS
Produktsammanfattning:
Active ingredient group (AIG) number: 0117292002; AHFS:
Bemyndigande status:
CANCELLED PRE MARKET
Tillstånd datum:
2018-08-01
Produktens egenskaper
_ _
PRODUCT MONOGRAPH
SANDOZ CEFTRIAXONE
Sterile Ceftriaxone for Injection BP
1 G AND 2 G CEFTRIAXONE PER VIAL (INCORPORATED AS CEFTRIAXONE SODIUM)
ANTIBIOTIC
Sandoz Canada Inc.
Date of Revision: January 15, 2010
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
CONTROL # : 133307
_Sandoz Ceftriaxone _
_ Page 2 of 51_
_ _
TABLE OF CONTENTS
HEALTH PROFESSIONAL
INFORMATION.........................................................................
3
ACTION
.....................................................................................................................................
3
INDICATIONS AND CLINICAL
USES...................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS...............................................................................................................................
4
PRECAUTIONS.........................................................................................................................
6
ADVERSE
REACTIONS...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
....................................................... 10
DOSAGE AND
ADMINISTRATION.....................................................................................
10
ADMINISTRATION................................................................................................................
11
PHARMACEUTICAL
INFORMATION.................................................................................
13
DRUG
SUBSTANCE...............................................................................................................
13
DRUG
PRODUCT....................................................................................................................
13
RECONSTITUTION
.......................................................................................
Läs hela dokumentet
